ERBB2 and breast cancer: In breast cancer, olaparib and talazoparib demonstrated significant clinical benefits over chemotherapy in PFS and ORR for germline BRCA‐mutated, HER2‐negative metastatic or locally advanced breast cancer based on the phase III OlympiAD and EMBRACA trials, respectively.